Hormone Therapy and the Progression of Coronary-Artery Atherosclerosis in Postmenopausal Women

Authors:
  • WMWendy J. Mack
    Wendy J. Mack
  • SAStanley P. Azen
    Stanley P. Azen
  • RLRoger A. Lobo
    Roger A. Lobo
  • DSDonna Shoupe
    Donna Shoupe
  • PMPeter R. Mahrer
    Peter R. Mahrer
  • DFDavid P. Faxon
    David P. Faxon
  • LCLinda Cashin-Hemphill
    Linda Cashin-Hemphill
  • MSMiguel E. Sanmarco
    Miguel E. Sanmarco
  • WFWilliam J. French
    William J. French
  • TSThomas L. Shook
    Thomas L. Shook
  • TGThomas D. Gaarder
    Thomas D. Gaarder

Abstract
In postmenopausal women with coronary artery disease, conjugated equine estrogen with or without continuous administration of medroxyprogesterone acetate has failed to slow the progression of atherosclerosis. Whether 17β-estradiol (the endogenous estrogen molecule) alone or administered sequentially with medroxyprogesterone acetate can slow the progression of atherosclerosis is unknown.

This publication has 37 references indexed in Scilit: